AnPac Bio Signs a Record Multi-Million Dollar Contract for Cancer Screening
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) has signed a groundbreaking three-year collaboration with Beijing Yuan Jian Health Management Co., Ltd. for cancer screening. This contract includes a minimum of 76,000 paid tests valued at over $3 million, significantly surpassing previous agreements. CEO Dr. Chris Yu highlighted the growing acceptance of their innovative cancer screening technology in the healthcare market, emphasizing prospects for ongoing growth and sustainability. The company is also advancing its commercialization efforts in the U.S. with plans for a new lab in Philadelphia.
- Secured a three-year collaboration contract worth over $3 million.
- Contract includes a minimum of 76,000 paid cancer screening tests, marking a substantial increase.
- Growing acceptance of innovative cancer screening technology in the healthcare market.
- None.
SAN JOSE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has entered into a record, three-year strategic cancer screening collaboration contract with Beijing Yuan Jian Health Management Co., Ltd. in China, which has been a client of the Company for the past two years. This contract contains a minimum of 76,000 paid cancer screening tests, including at least 6,000 paid tests in 2020, 25,000 paid tests in 2021, and 45,000 paid tests in 2022. The total value of the contract is slightly over US
AnPac Bio’s CEO, Dr. Chris Yu, remarked, “Our novel cancer screening technology and tests are receiving increasing acceptance from the healthcare market. Due to our CDA tests’ outstanding performance and competitive costs, we expect to see significant continued market opportunities and growth potential in China.”
Dr. Chris Yu continued, “Our ability to continue receiving multi-year sales contracts demonstrates that our novel technology, quality and service have long sustainability with customers in the market place. At the same time, we are pushing ahead with our commercialization plan of CDA cancer screening tests in the US, with on-going commercialization efforts at our San Jose lab and opening of our second lab at Philadelphia.”
About Beijing Yuan Jian Health Management Co., Ltd.
Beijing Yuan Jian Health Management Co., Ltd. is a Chinese health management firm with a focus on health care management. Its team consists of well-known experts and professionals in the fields of health care management and medicine, and it has collaborated with various well-known academic and medical institutions including universities, hospitals and other healthcare organizations in China and the U.S.
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 121 issued patents as of December 31, 2019. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. In a 2019 market research report by Frost & Sullivan, AnPac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. AnPac Bio’s CDA technology has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.
For more information, please visit: https://www.Anpacbio.com.
For investor and media inquiries, please contact:
Company:
Phil Case, Marketing and Investor Relations
Phone: +1-267-810-6776 (US)
Email: phil_case@AnPacbio.com
Investor Relations:
Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
Email: tina.xiao@ascent-ir.com
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,” “likely,” "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
FAQ
What is the significance of the new contract for AnPac Bio (ANPC)?
How many cancer screening tests are included in the AnPac Bio contract?
What is the total value of AnPac Bio's new collaboration contract?
When does the contract with Beijing Yuan Jian Health Management Co., Ltd. commence?
What are the growth prospects for AnPac Bio following this contract?
